Related references
Note: Only part of the references are listed.Angiocrine Hepatocyte Growth Factor Signaling Controls Physiological Organ and Body Size and Dynamic Hepatocyte Proliferation to Prevent Liver Damage during Regeneration
Xue-jun Zhang et al.
AMERICAN JOURNAL OF PATHOLOGY (2020)
Expression of c-Met in Primary and Recurrent Hepatocellular Carcinoma
Yoshinari Asaoka et al.
ONCOLOGY (2020)
A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
Ryo Fujita et al.
CANCER BIOLOGY & THERAPY (2020)
Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy
Li Liu
INFECTIOUS AGENTS AND CANCER (2020)
Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression
Rongdang Fu et al.
MEDICAL ONCOLOGY (2020)
The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance
Xing Huang et al.
AUTOPHAGY (2019)
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
Michael Teufel et al.
GASTROENTEROLOGY (2019)
Has PD-1 MET Its Match in Hepatocellular Carcinoma?
Joseph W. Franses et al.
GASTROENTEROLOGY (2019)
MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1
Hui Li et al.
GASTROENTEROLOGY (2019)
Activated hepatic stellate cells promote progression of post-heat residual hepatocellular carcinoma from autophagic survival to proliferation
Rui Zhang et al.
INTERNATIONAL JOURNAL OF HYPERTHERMIA (2019)
From NASH to HCC: current concepts and future challenges
Quentin M. Anstee et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma
Enrique Soto-Perez-de-Celis et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium
Robin Guo et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
LBA3IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
A-L Cheng et al.
ANNALS OF ONCOLOGY (2019)
Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma
Weiting Liao et al.
LIVER INTERNATIONAL (2019)
SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models
Chang-yong Yang et al.
ACTA PHARMACOLOGICA SINICA (2019)
Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response
Bridget P. Keenan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives
T. Mocan et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
Preclinical pharmacokinetics of a novel anti-c-Met antibody-drug conjugate, SHR-A1403, in rodents and non-human primates
Changyong Yang et al.
XENOBIOTICA (2019)
Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway
Qing-Feng Xiang et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2019)
Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis
Amir Shlomai et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2019)
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
Shukui Qin et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis
W. L. Hasler et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2018)
Deguelin suppresses angiogenesis in human hepatocellular carcinoma by targeting HGF-c-Met pathway
Ming Li et al.
ONCOTARGET (2018)
The Effect of Selective c-MET Inhibitor on Hepatocellular Carcinoma in the MET-Active, β-Catenin-Mutated Mouse Model
Na Zhan et al.
GENE EXPRESSION (2018)
A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China
Lingling Sun et al.
INTEGRATIVE CANCER THERAPIES (2018)
miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT
Demin Jiao et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma
Yu Zhang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Antibody-Drug Conjugates for Cancer Treatment
John M. Lambert et al.
ANNUAL REVIEW OF MEDICINE, VOL 69 (2018)
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
Lorenza Rimassa et al.
LANCET ONCOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma
Sadakatsu Ikeda et al.
ONCOLOGIST (2018)
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
J. K. Sabari et al.
ANNALS OF ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review
Philippe Rochigneux et al.
BMC CANCER (2018)
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
John H. Strickler et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Role of traditional Chinese medicine in the management of patients with hepatocellular carcinoma
Sheng-Yan Xi et al.
WORLD JOURNAL OF HEPATOLOGY (2018)
Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma
Li-Jie Ma et al.
THERANOSTICS (2018)
A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
Thomas C. C. Yau et al.
CLINICAL CANCER RESEARCH (2017)
ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence
Jieyi Wang et al.
CLINICAL CANCER RESEARCH (2017)
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2017)
Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells
Peng Han et al.
MOLECULAR ONCOLOGY (2017)
Resveratrol suppresses human hepatocellular carcinoma via targeting HGF-c-Met signaling pathway
Feng Gao et al.
ONCOLOGY REPORTS (2017)
PD-1 immunobiology in autoimmune hepatitis and hepatocellular carcinoma
Colleen S. Curran et al.
SEMINARS IN ONCOLOGY (2017)
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study
R. K. Kelley et al.
ANNALS OF ONCOLOGY (2017)
Synergistic Inhibitory Effect of Traditional Chinese Medicine Astragaloside IV and Curcumin on Tumor Growth and Angiogenesis in an Orthotopic Nude-Mouse Model of Human Hepatocellular Carcinoma
Shuo Zhang et al.
ANTICANCER RESEARCH (2017)
Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options
Celina Ang et al.
JOURNAL OF SURGICAL ONCOLOGY (2016)
Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells
Zeynep Firtina Karagonlar et al.
CANCER SCIENCE (2016)
Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma
Andrew X. Zhu et al.
JOURNAL OF HEPATOLOGY (2016)
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib
Lorenza Rimassa et al.
ONCOTARGET (2016)
Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date
Daniel Pievsky et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2016)
Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors
Takuji Okusaka et al.
CANCER SCIENCE (2015)
The Role of Autophagy in Hepatocellular Carcinoma
Yoo Jin Lee et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
MET is required for the recruitment of anti-tumoural neutrophils
Veronica Finisguerra et al.
NATURE (2015)
The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma
Steven N. Steinway et al.
PLOS ONE (2015)
MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocellular carcinoma
Young Wha Koh et al.
TUMOR BIOLOGY (2015)
Mechanism of QHF-cisplatin against hepatocellular carcinoma in a mouse model
Tao Chen et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
Igor Puzanov et al.
INVESTIGATIONAL NEW DRUGS (2015)
Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
Qingfeng Xiang et al.
CLINICAL CANCER RESEARCH (2014)
Met as a therapeutic target in HCC: Facts and hopes
Silvia Giordano et al.
JOURNAL OF HEPATOLOGY (2014)
An allosteric switch for pro-HGF/Met signaling using zymogen activator peptides
Kyle E. Landgraf et al.
NATURE CHEMICAL BIOLOGY (2014)
Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors
Yung-Jue Bang et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Antibody-Drug Conjugates in Cancer Therapy
Eric L. Sievers et al.
ANNUAL REVIEW OF MEDICINE, VOL 64 (2013)
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis
A. Santoro et al.
BRITISH JOURNAL OF CANCER (2013)
Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma
Shunsuke Kondo et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
Armando Santoro et al.
LANCET ONCOLOGY (2013)
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Josep M. Llovet et al.
CLINICAL CANCER RESEARCH (2012)
Spontaneous regression of hepatocellular carcinoma is most often associated with tumour hypoxia or a systemic inflammatory response
Jonathan I. Huz et al.
HPB (2012)
A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
Xiangdong Liu et al.
CLINICAL CANCER RESEARCH (2011)
c-Met Represents a Potential Therapeutic Target for Personalized Treatment in Hepatocellular Carcinoma
Hanning You et al.
HEPATOLOGY (2011)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells
Kehy L. Mueller et al.
CANCER RESEARCH (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
Des-γ-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma
M Suzuki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma
P Vejchapipat et al.
JOURNAL OF GASTROENTEROLOGY (2004)
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
S Pennacchietti et al.
CANCER CELL (2003)
Met receptor tyrosine kinase: enhanced signaling through adapter proteins
KA Furge et al.
ONCOGENE (2000)
Share Paper
